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Abstract. 
 
Eps15 has been identified as a substrate of 
the EGF receptor tyrosine kinase. In this report, we 
show that activation of the EGF receptor by either 
EGF or TGF-
 
a
 
 results in phosphorylation of Eps15. 
Stimulation of cells with PDGF or insulin did not lead 
to Eps15 phosphorylation, suggesting that phosphoryla-
tion of Eps15 is a receptor-specific process. We demon-
strate that Eps15 is constitutively associated with both 
 
a
 
-adaptin and clathrin. Upon EGF stimulation, Eps15 
and 
 
a
 
-adaptin are recruited to the EGF receptor. Using 
a truncated EGF receptor mutant, we demonstrate that 
the regulatory domain of the cytoplasmic tail of the 
EGF receptor is essential for the binding of Eps15. 
Fractionation studies reveal that Eps15 is present in cell 
fractions enriched for plasma membrane and endoso-
mal membranes. Immunofluorescence studies show 
that Eps15 colocalizes with adaptor protein-2 (AP-2) 
and partially with clathrin. No colocalization of Eps15 
was observed with the early endosomal markers rab4 
and rab5. These observations indicate that Eps15 is 
present in coated pits and coated vesicles of the clath-
rin-mediated endocytic pathway, but not in early endo-
somes. Neither AP-2 nor clathrin are required for the 
binding of Eps15 to coated pits or coated vesicles, since 
in membranes lacking AP-2 and clathrin, Eps15 still 
shows the same staining pattern. These findings suggest 
that Eps15 may play a critical role in the recruitment of 
active EGF receptors into coated pit regions before en-
docytosis of ligand-occupied EGF receptors.
 
G
 
rowth
 
 factors such as EGF are involved in many
physiological and pathological processes, includ-
ing cell growth, differentiation, inflammation, and
cancer. EGF receptor activation is thought to occur upon
ligand-induced receptor dimerization leading to receptor
cross-phosphorylation (Schlessinger, 1988; Ullrich and
Schlessinger, 1990). The tyrosine-phosphorylated receptor
provides for docking sites for SH2 domain containing sig-
nal transducing molecules such as Grb2 and phospholi-
pase-C
 
g
 
1. Complex formation initiates a signaling cascade
that leads to changes in gene expression and cell division.
Inactivation of the EGF receptor occurs by several mecha-
nisms such as a reduction in receptor affinity (a process
that is called receptor transmodulation [Northwood and
Davis, 1990]), by receptor dephosphorylation, by phos-
photyrosine phosphatases (Faure et al., 1992), and by re-
ceptor downregulation (for review see Sorkin and Waters,
1993). Receptor downregulation includes the endocytosis
of activated receptors, resulting in the removal of acti-
vated receptors from the cell surface and the subsequent
degradation in lysosomes. The importance of downregula-
tion is stressed by the observation that receptors that are
unable to undergo ligand-induced internalization can facil-
itate cellular transformation (Wells et al., 1990) and tumor
formation (Masui et al., 1991).
EGF receptor endocytosis is achieved by a constitutive
pathway and a ligand-induced pathway (for review see
Sorkin and Waters, 1993). The EGF-induced, receptor-
mediated endocytotic pathway occurs via specialized coated
pit regions in the plasma membrane. These regions con-
tain a number of proteins, including the adaptor proteins
(APs)
 
1
 
 and the heavy and light chains of clathrin that form
the clathrin lattice (for review see Schmid, 1992). It has
been shown recently that kinase-deficient receptors fail to
undergo ligand-induced sequestration into coated pits
(Lamaze and Schmid, 1995) and that, as a result, kinase-
deficient receptors are not internalized via coated vesicles.
Recruitment into coated pits could be restored by the ad-
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Abbreviations used in this paper
 
: AP, adaptor protein; CSLM, confocal
laser scanning microscope; G, vesicular stomatitis virus G protein; HC,
heavy chain; LC, light chain; NH, hemagglutinin; TAPS, 
 
N
 
-Tris[hy-
droxymethyl]methyl-3-amino-propanesulfonic acid buffer.
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dition of a soluble EGF receptor tyrosine kinase. There-
fore, it has been proposed that the phosphorylation of an-
other protein, an as yet unknown EGF receptor substrate,
is required for the efficient recruitment of EGF receptors
into coated pits (Lamaze and Schmid, 1995).
EGF receptor activation leads to the phosphorylation of
various proteins. Recently, two new EGF receptor sub-
strates, Eps15 (EGF receptor pathway substrate clone No.
15) and Eps15R (Eps15 related) have been described
(Fazioli et al., 1993; Schumacher et al., 1995). Eps15 and
Eps15R are homologous proteins showing 47% identity
(Wong et al., 1995). The apparent molecular mass of both
proteins is 142 kD, and they consist of three structural do-
mains. Domain I is the putative regulatory domain, which
contains a candidate tyrosine phosphorylation site, EF
hand-type calcium-binding domains (Fazioli et al., 1993),
and three protein binding domains (Wong et al., 1995).
Domain II has the features of a coiled-coil structure and
domain III exhibits repeated DPF motifs, a motif that is
conserved in several methyl transferases, and a proline-
rich motif that can bind in vitro to the SH3 domain of c-Crk
and v-Crk (Schumacher et al., 1995). Eps15 has homology
with the yeast protein End3, which is involved in receptor-
mediated endocytosis of the 
 
a
 
 factor in 
 
Saccharomyces
cerevisiae
 
 (Benedetti et al., 1994). Recently, further evi-
dence for a possible role of Eps15 in endocytosis origi-
nated from the observation that Eps15 is associated with
AP-2 (Benmerah et al., 1995). Analysis of the binding sites
revealed that domain III of Eps15 binds directly to the
COOH-terminal appendage (ear) of 
 
a
 
-adaptin (Benmerah
et al., 1996).
In this paper, we have investigated the function of Eps15
in the ligand-induced endocytosis of the EGF receptor.
We show that in addition to the association of Eps15 to
 
a
 
-adaptin, Eps15 also associates with the EGF receptor
and with the clathrin light chain (LC). The interaction of
Eps15 with 
 
a
 
-adaptin and clathrin LC is not changed by
EGF treatment, whereas a strong increase is observed in
the association of the EGF receptor with either Eps15 and
 
a
 
-adaptin after EGF stimulation. Furthermore, we dem-
onstrate that the Eps15 binding site of the EGF receptor is
located in the regulatory domain of the intracellular part
of the EGF receptor. Localization studies using the confo-
cal scanning laser microscope (CSLM) show a strong colo-
calization of Eps15 with AP-2 and a partial colocalization
of Eps15 with clathrin. In contrast, no colocalization of
Eps15 with either rab4 or rab5 was found. This suggests a
function for Eps15 in coated pits and coated vesicles, but
not in early endosomes. Our data may indicate a func-
tional role for Eps15 in ligand-induced endocytosis of
EGF receptors.
 
Materials and Methods
 
Tissue Culture
 
Swiss 3T3 fibroblasts, HER14 fibroblasts (NIH 3T3 cells stably trans-
fected with human EGF receptor cDNA), A14 fibroblasts (NIH 3T3 cells
stably transfected with insulin receptor cDNA), T963 fibroblasts (NIH
3T3 cells stably transfected with EGF receptor cDNA truncated at amino
acid 963), and CHO cells stably transfected with rab4 cDNA tagged with
hemagglutinin (NH) and rab5 tagged with vesicular stomatitis virus G pro-
tein (G; van der Sluijs, P., manuscript submitted for publication) were cul-
tured in DME (Gibco, Paisley, UK) supplemented with 7.5% vol/vol FCS
(Gibco) in a humidified atmosphere at 37
 
8
 
C.
 
Immunoprecipitation Experiments
 
Cells were grown in 100-mm dishes (Costar Corp., Cambridge, MA) to
80% confluency. Cells were serum starved in DME–0% vol/vol FCS for
24 h before stimulation with 50 ng/ml EGF, 20 ng/ml PDGF-BB, 50 ng/ml
TGF-
 
a
 
, or 1 
 
m
 
g/ml insulin. Cells were lysed in RIPA buffer (20 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 0.5% Triton X-100. 0.1% SDS, 1 mM EDTA,
1 mM PMSF, 1 mM benzamidine, 100 mM NaF, 1 mM Na
 
3
 
VO
 
4
 
) at 4
 
8
 
C for
10 min and centrifuged for 5 min at 12,000 
 
g
 
 in an Eppendorf centrifuge.
The supernatants were incubated with 25 
 
m
 
l of a 1:1 suspension of protein
A–Sepharose in RIPA buffer for 1 h at 4
 
8
 
C. The samples were centrifuged
and incubated with either anti-Eps15 antibody (rabbit polyclonal; Schu-
macher et al., 1995), anti-Eps15R antibody (rabbit polyclonal; Schuma-
cher et al., 1995), anti–clathrin LC antibody (rabbit polyclonal, a gift from
Dr. E. Ungewickell, Max-Planck Institut Für Biochemie, Martinsried,
FRG), or anti–EGF receptor (mouse monoclonal clone No. 528; Santa
Cruz Biotechnology, Santa Cruz, CA) for 2 h at 4
 
8
 
C. Protein A–Sepharose
was subsequently added, and after a further 2-h incubation, the immuno-
precipitates were washed three times, once with RIPA buffer, once with
high salt buffer (20 mM Tris-HCl, pH 7.4, 0.5 M NaCl, 1% Triton X-100, 1
mM PMSF, 1 mM benzamidine, 1 mM Na
 
3
 
VO
 
4
 
), and finally with low salt
buffer (20 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 1% Triton X-100, 1 mM
PMSF, 1 mM benzamidine, 1 mM Na
 
3
 
VO
 
4
 
). The samples were boiled in
20 
 
m
 
l Laemmli sample buffer for 5 min. For the preparation of total cell ly-
sates, cells were immediately lysed in RIPA buffer. The samples were sep-
arated by 8% SDS-PAGE and the Western blot was probed with rabbit
polyclonal antibodies against Eps15 and anti–clathrin LC, or with mouse
mAbs against 
 
a
 
-adaptin (a gift from Dr. F. Brodsky, University of Califor-
nia, San Francisco, CA), anti–EGF receptor, anti–PDGF receptor (mouse
monoclonal; Upstate Biotechnology, Inc., Lake Placid, NY), or antiphos-
photyrosine (mouse monoclonal; Transduction Laboratories, Lexington,
KY). Immunocomplexes were detected using enhanced chemilumines-
cence (Renaissance; DuPont New England Nuclear, Boston, MA) with
peroxidase-conjugated goat anti–rabbit or rabbit anti–mouse Ig (Jackson
ImmunoResearch, West Grove, PA). Protein bands were analyzed by
densitometry (Personal Densitometer SI; Molecular Dynamics Inc.,
Sunnyvale, CA) and quantified using the ImageQuaNT software, version
4.2, Microsoft for Windows.
 
Cell Fractionation
 
Cell fractionation and analysis of the different fractions was carried out by
differential centrifugation as described by Evans (1992). HER14 fibro-
blasts were washed once in PBS and once in homogenation buffer (250
mM sucrose, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM PMSF, 1 mM
benzamidine). Cells were collected in homogenation buffer and homoge-
nized by 10 passages through a 24-G needle. Whole cells and nuclei were
removed by centrifugation for 5 min at 1,000 
 
g
 
 at 4
 
8
 
C. To clear the super-
natant from the remaining nuclei, the cell lysate was pelleted through a 2-M
sucrose layer. The supernatant was subsequently centrifuged for 12 min at
10,000 
 
g
 
 at 4
 
8
 
C to give a pellet that was washed two times with homogena-
tion buffer. The supernatant of the 10,000-
 
g
 
 spin was subsequently centri-
fuged at 150,000 
 
g
 
 for 30 min at 4
 
8
 
C. The remaining supernatant was con-
sidered as the cytosol. The separate fractions were assayed for various
enzyme markers. The highest activity of lactate dehydrogenase was found
in the cytosol. The highest activities of 5
 
9
 
 nucleotidase and acid phos-
phatase were found in the 10,000-
 
g
 
 pellet, demonstrating that plasma
membrane vesicles and lysosomes are enriched in this fraction. NADH cy-
tochrome 
 
c
 
 reductase and anti–
 
a
 
-adaptin antibodies were used as markers
for the ER and coated vesicles, respectively, and were both enriched in
the 150,000-
 
g
 
 pellet.
 
Immunofluorescence Microscopy
 
Cells were grown for 3 d in 12-well plates on glass coverslips in DME-
7.5% vol/vol FCS. Cells were fixed in 3% formaldehyde (Polysciences,
Warrington, PA) in PBS for a minimum of 30 min. Cells were washed
twice with PBS and permeabilized with 0.2% Triton X-100 in PBS for 5
min. The cells were subsequently washed twice with PBS and incubated in
50 mM glycine in PBS for 10 min. Cells were washed twice in 0.2% gelatin
(Merck, Darmstadt, Germany) in PBS and incubated with either anti-
Eps15 serum, anti–clathrin heavy chain (HC), anti–
 
a
 
-adaptin, anti-NH 
van Delft et al. 
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(Bottger et al., 1996), or anti-G antibodies (Kreis and Lodish, 1986) di-
luted in 0.2% gelatin/PBS for 45 min at room temperature. Cells were
washed in 0.2% gelatin/PBS and incubated with either goat anti–rabbit
conjugated to FITC or goat anti–mouse conjugated to Texas red for 30
min at room temperature, followed by four washes in 0.2% gelatin/PBS.
Finally, cells were embedded in 10% Mowiol 4-88, 25% glycerol, 100 mM
Tris, pH 8.5, containing 1 mg/ml 
 
p
 
-phenylene-diamine (PPD; Sigma, St.
Louis, MO) and examined in a CSLM (Lasersharp mrc-500; Bio Rad,
Hemel Hempsted, UK) or in a Leitz Orthoplan microscope equipped with
epi-illumination.
Image processing and analysis was performed following the method of
van Steensel et al. (1996). In short, a cross-correlation analysis of the red
and green images was calculated by shifting the red image over a distance
of 
 
D
 
x pixels in the 
 
x
 
 direction with respect to the green image (with
 
2
 
20
 
<D
 
x
 
<
 
20). For each value of 
 
D
 
x, the Pearson’s correlation coefficient
 
r
 
P
 
 was calculated by a computer program (written in BASIC), according
to the following formula:
where 
 
R
 
i
 
 (red) and 
 
G
 
i
 
 (green) are the values of pixel 
 
i
 
 and 
 
R
 
av
 
 and 
 
G
 
av
 
 are
the average values of 
 
R
 
i
 
 and 
 
G
 
i
 
, respectively. The cross-correlation func-
tion was obtained by plotting r
 
P
 
 against 
 
D
 
x.
 
Stripping of Coat Proteins from Plasma
Membrane Fragments
 
HER14 cells were grown on glass coverslips coated with poly-
 
l
 
-lysine
(1 mg/ml). Membrane fragments were prepared by rapid freeze-thaw rup-
turing of cells (Chang et al., 1993
 
a
 
). Clathrin coat proteins were removed
by four washing steps in ice-cold 20 mM 
 
N
 
-Tris[hydroxymethyl]methyl-3-
amino-propanesulfonic acid buffer (TAPS), pH 9.2, incubation in TAPS
buffer for 20 min at 4
 
8
 
C, followed by four washes in the same buffer. AP-2
coat proteins were removed by four washing steps in ice-cold Tris buffer
(0.5 M Tris, pH 7.0, 1 mM DTT), incubation for 20 min in Tris buffer at
4
 
8
 
C, followed by four washes in the same buffer. The membranes were
subsequently washed seven times at 4
 
8
 
C with an ice-cold buffer containing
36.4 mM Hepes, pH 7.0, 68.2 mM KCl, 4.1 mM Mg-acetate, 1 mM DTT,
1 mM PMSF, and 1 mM benzamidine, were fixed in 3% formaldehyde in
20 mM Hepes, pH 6.8, 3 mM EGTA, 5 mM MgCl
 
2
 
; and 100 mM KCl, and
were subsequently incubated for 1 h at 37
 
8
 
C in PBS supplemented with
0.2% gelatin, 1% BSA, and 50 mM glycine. Membranes were stained with
either anti-Eps15, anti–
 
a
 
-adaptin, or anti-clathrin antibodies, and further
processed for immunofluorescence microscopy, as described above.
 
Results
 
Eps15 Is Phosphorylated after Stimulation
with EGF and TGF-
 
a
 
, but Not after Stimulation
with PDGF or Insulin
 
Eps15 has been described as a substrate of the EGF receptor
(Fazioli et al., 1993). After stimulation of the EGF recep-
tor, 
 
z
 
30% of the total pool of Eps15 was tyrosine phos-
phorylated (Fazioli et al., 1993). To determine whether
Eps15 is a specific substrate of the EGF receptor, Eps15
was immunoprecipitated from cells treated with either
EGF, insulin, or PDGF, and the phosphorylated Eps15
was detected using an antibody against phosphotyrosine
residues. For these experiments, antibodies that were
raised against either Eps15 or Eps15R were used (Schu-
macher et al., 1995). In HER14 cells, very low levels of
Eps15R protein were detected, indicating that Eps15R is
not highly expressed in mouse fibroblasts (data not shown).
This is in agreement with previous studies using HeLa
cells (Schumacher et al., 1995). Therefore, in this study, we
have concentrated our efforts on the detection of the
much more abundant Eps15 protein.
rP
S
i
Ri Rav – () G i G av – () ×
S
i R i R av – ()
2 S
i G i G av – ()
2 ×
----------------------------------------------------------------------------- =
 
Three different cell types were used: HER14 cells con-
taining 
 
z
 
4 
 
3
 
 10
 
5
 
 EGF receptors per cell (Rotin et al.,
1992), A14 cells containing 
 
z
 
05 
 
3
 
 10
 
5
 
 insulin receptors
(Burgering et al., 1991), and Swiss 3T3 cells with 
 
z
 
4 
 
3
 
 10
 
5
 
PDGF receptors per cell (Bowen-Pope and Russell, 1982).
These fibroblast cell lines were chosen because of their
similar amounts of the respective cell surface receptors.
Cells were serum starved overnight and were either left
unstimulated or stimulated for 2, 10, or 30 min with 50 ng/ml
EGF, 20 ng/ml PDGF, or 1 
 
m
 
g/ml insulin. Eps15 immuno-
precipitates were Western blotted and probed with an an-
tiphosphotyrosine antibody. A clear phosphorylation of
Eps15 was seen in HER14 cells after stimulation with
EGF (Fig. 1 
 
A
 
). Furthermore, EGF stimulation induced a
transient mobility shift of phosphorylated Eps15, as seen
on the Western blot by a shift in molecular mass from 142
to 150 kD. After 10 min of EGF stimulation, almost 50%
of the Eps15 was shifted to the 150-kD form. At this time,
it is unknown whether this shift is caused by hyperphos-
phorylation or to another type of posttranslational modifi-
cation. No phosphorylation of Eps15 was observed in A14
cells that were stimulated with insulin (Fig. 1 
 
B
 
) nor in
Swiss 3T3 cells stimulated with PDGF (Fig. 1 
 
C
 
). Control
experiments showed that Eps15 was present in both cell
types (Fig. 1, 
 
B
 
 and 
 
C
 
), and that stimulation of the cells
with EGF induced Eps15 phosphorylation (data not shown).
Furthermore, Western blots of cell lysates from the same
samples indicated the presence and phosphorylation of
both the insulin receptor and PDGF receptor (Fig. 1, 
 
B
 
and 
 
C
 
). A14 cells and Swiss 3T3 cells both contained a sub-
stantial amount of the 122-kD protein next to the 142-kD
Eps15 band (Fazioli et al., 1993), in contrast to HER14
cells, where a 122-kD band was not detected. This 122-kD
band may reflect a degradation product of Eps15 (Fazioli
et al., 1993).
These data show that Eps15 is phosphorylated specifi-
cally by activated EGF receptors, and not by insulin recep-
tors or PDGF receptors. To obtain further indication for
the EGF receptor specificity of Eps15 phosphorylation, an
EGF-related peptide was used: TGF-
 
a
 
. Like EGF, TGF-
 
a
 
binds and activates the EGF receptor (Winkler et al.,
1989). HER14 cells were either left unstimulated or stimu-
lated with 50 ng/ml TGF-
 
a
 
, Eps15 immunoprecipitates
were separated by SDS-PAGE, and Western blots were
probed with an antiphosphotyrosine antibody. Stimulation
of these cells with TGF-
 
a
 
 showed a clear phosphorylation
of Eps15 (Fig. 1 
 
A
 
). However, TGF-
 
a
 
–induced phosphory-
lation kinetics differed from EGF-stimulated phosphory-
lation. TGF-
 
a
 
–induced phosphorylation peaks at 2 min,
whereas EGF-induced phosphorylation peaks at 10 min.
Together, these data show that Eps15 is a specific sub-
strate of the EGF receptor tyrosine kinase, but not of the
PDGF or insulin receptor tyrosine kinase.
 
Association of Eps15 with the EGF Receptor,
a-Adaptin, and Clathrin LC
Eps15 has homology with the yeast protein End3, a pro-
tein involved in a factor endocytosis (Benedetti et al.,
1994). Moreover, it has recently been shown that Eps15 is
constitutively associated with a-adaptin (Benmerah et al.,
1995). Therefore, we wanted to determine whether Eps15The Journal of Cell Biology, Volume 136, 1997 814
is associated with proteins other than a-adaptin that are
involved in the receptor-mediated endocytosis of EGF re-
ceptors. HER14 cells were serum starved and either left
unstimulated or treated with 50 ng/ml EGF. Subsequently,
EGF receptors were immunoprecipitated from cell lysates
and the samples were separated by SDS-PAGE. Western
blots were analyzed for the presence of Eps15 and a-adaptin.
A modest association between the EGF receptor and Eps15
was observed in unstimulated cells (Fig. 2 A, lane 1).
However, stimulation of the cells with EGF resulted in a
dramatic increase in the binding of Eps15 to the EGF re-
ceptor. Also, the tyrosine-phosphorylated and the post-
translational modified form of Eps15 was observed in the
EGF receptor immunoprecipitates (Fig. 2 A, lane 2). Simi-
larly, an EGF receptor immunoprecipitate probed with
anti–a-adaptin showed an association of the EGF receptor
with AP-2, which increased upon EGF stimulation (Fig.
2 A, lanes 3 and 4). The double band that is visible on the
Western blot probed with anti–a-adaptin represents the
aa and the ac form of this protein (Boll et al., 1995).
The effect of EGF on the association of Eps15 and AP-2
was further investigated. Eps15 was immunoprecipitated
from unstimulated and EGF-treated cells, and Western
blots were probed with anti–a-adaptin antibody (Fig. 2 B,
lanes 1 and 2). EGF treatment did not affect the interac-
tion between Eps15 and AP-2, which suggests that Eps15–
AP-2 binding is EGF independent.
The adaptor proteins have been shown to bind to the
clathrin coat of the coated vesicle (Pearse and Crowther,
1987). To check the association of Eps15 with clathrin, we
investigated whether clathrin could be coimmunoprecipi-
tated with Eps15 in an EGF-dependent manner. HER14
cells were treated with EGF or left untreated, and clathrin
was immunoprecipitated using a specific anti–clathrin LC
antibody. The Western blot was subsequently probed with
an anti-Eps15 antibody and revealed an association of
Eps15 with the clathrin LC. This association was not al-
tered by EGF stimulation. Furthermore, the posttransla-
tional modified form of Eps15 was present in the clathrin
immunoprecipitates, indicating that both Eps15 forms as-
sociate to clathrin (Fig. 2 B, lanes 3 and 4). In control ex-
periments, no Eps15 was found when the immunoprecipi-
tation was performed with a nonspecific antibody (data
not shown). In conclusion, these experiments show that
Eps15 is associated with both a-adaptin and clathrin LC
and that these interactions are not altered by EGF treat-
ment. In contrast, EGF induces a strong increase in the
binding of the EGF receptor to both Eps15 and a-adaptin.
The Regulatory Domain of the EGF Receptor Is 
Required for Association with Eps15
EGF stimulation of HER14 fibroblasts resulted in a strong
increase in the binding of Eps15 to the EGF receptor. This
interaction between Eps15 and the EGF receptor has
never been described before, and thus the binding site for
Eps15 on the EGF receptor is unknown. Fazioli and co-
workers (1993) have shown that the juxtamembrane region
of the EGF receptor and an EGF/erbB-2 receptor chimera
is important for phosphorylation of Eps15. However, oth-
ers have shown that a region in the regulatory domain in
the COOH-terminal tail of the receptor, encompassing
residues 991–1021, is critical for Eps15 phosphorylation
(Alvarez et al., 1995). This particular region of the EGF
receptor is a part of the region that mediates endocytosis
Figure 1. Eps15 is phosphorylated after stimula-
tion with EGF and TGF-a, but not after stimula-
tion with PDGF or insulin. (A) Eps15 immuno-
precipitates from HER14 cells that were either
mock treated or stimulated for 2, 10, and 30 min
with 50 ng/ml EGF or 50 ng/ml TGF-a. The pro-
teins were separated on 8% SDS-PAGE, and the
Western blot was probed with antiphosphoty-
rosine antibody. (B) Eps15 immunoprecipitates
and lysates from A14 cells that were either mock
treated or stimulated for 2, 10, and 30 min with 1
mg/ml insulin. Western blots were probed with
an antiphosphotyrosine antibody, an anti-Eps15
antibody, and an anti–insulin receptor antibody.
(C) Eps15 immunoprecipitates and lysates from Swiss 3T3 cells that were left unstimulated or stimulated for 2, 10, and 30 min with 20
ng/ml PDGF. Western blots were probed with an antiphosphotyrosine antibody, an anti-Eps15 antibody, and an anti–PDGF receptor
antibody.
Figure 2. Association of Eps15 with the EGF receptor, a-adap-
tin, and clathrin LC. (A) EGF receptor immunoprecipitates from
HER14 cells that were either mock treated or stimulated for 10
min with 50 ng/ml EGF. The proteins were separated on 8%
SDS-PAGE, and the Western blots were probed with anti-Eps15
or anti–a-adaptin (AP-2) antibody. (B) Eps15 and clathrin LC
(Cla) immunoprecipitates from HER14 cells that were left un-
stimulated or stimulated for 10 min with 50 ng/ml EGF. Western
blots were probed with an anti–a-adaptin or an anti-Eps15 anti-
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(Chen et al., 1989). We investigated whether the regula-
tory domain of the EGF receptor is involved in the bind-
ing of Eps15. A mutant EGF receptor that was truncated
at amino acid 963 was transfected into NIH 3T3 cells con-
taining no detectable EGF receptors (T963 cells). This
EGF receptor mutant still contains the juxtamembrane re-
gion, but lacks the regulatory domain including amino ac-
ids 991–1021. Control experiments showed that EGF-stim-
ulated endocytosis of EGF receptors was impaired in the
T963 cells (data not shown), which is in agreement with
previous studies (Chen et al., 1989; Chang et al., 1993b).
To check EGF-induced phosphorylation of Eps15, both
serum-starved HER14 and T963 fibroblasts were either
left unstimulated or stimulated with 50 ng/ml EGF for 10
min. Eps15 was subsequently immunoprecipitated, and
the samples were Western blotted and probed with an an-
tiphosphotyrosine antibody. A clear EGF-induced phos-
phorylation of Eps15 is seen in HER14 cells that contain
the wild-type receptor (Fig. 3 A, lanes 1 and 2). However,
the truncated T963 receptor is no longer able to phosphor-
ylate Eps15 (Fig. 3 A, lanes 3 and 4). As a control, auto-
phosphorylation of the intact EGF receptor and the T963
receptor is shown (Fig. 3 B). Although similar amounts of
EGF receptors were used in this assay, phosphorylation of the
wild-type EGF receptor is much stronger than that of the
truncated form because the main phosphorylation sites are
deleted in the T963 mutant in contrast to the wild-type re-
ceptor. Furthermore, to demonstrate that indeed the T963
receptor contains an active tyrosine kinase, we analyzed
angiotensin II phosphorylation, a specific substrate of the
EGF receptor. Both the intact EGF receptor, as well as
the truncated T963 receptor, showed a twofold increase in
kinase activity after EGF stimulation (data not shown).
To investigate the binding of Eps15 to the truncated
EGF receptor, cells were treated with EGF, and the EGF
receptor was immunoprecipitated using an anti–EGF re-
ceptor antibody directed against the extracellular domain
of the EGF receptor. These experiments revealed an EGF-
dependent coimmunoprecipitation of Eps15 with the wild-
type receptor (Fig. 4 A, lanes 1 and 2), but no coimmuno-
precipitation of Eps15 was seen with the T963 EGF receptor
mutant (Fig. 4 A, lanes 3 and 4). For both cell lines, similar
amounts of EGF receptors were immunoprecipitated, as
shown by Western blotting of the wild-type and mutant re-
ceptors (Fig. 4 B). As expected, the truncated receptor mi-
grated with a lower molecular weight, and the mobility
shift, caused by hyperphosphorylation, was not visible be-
cause of the deletion of the major autophosphorylation
sites. In conclusion, these experiments demonstrate that
the regulatory domain in the intracellular part of the EGF
receptor, previously shown to be important for receptor
endocytosis, is not only required for Eps15 phosphoryla-
tion, but also for Eps15 binding to the EGF receptor.
Subcellular Localization of Eps15
To analyze the possible role of Eps15 in endocytosis of the
EGF receptor further, we analyzed the subcellular local-
ization of Eps15 by biochemical fractionation. For these
experiments, HER14 cells were fractionated into a 1,000-g
pellet (1k), a 10,000-g pellet (10k), a 150,000-g pellet (150k),
and a cytosolic fraction, as described in Materials and
Methods. These fractions were analyzed for the presence
of specific marker proteins. The 1k pellet contained nuclei
and the cytoskeleton and was not used for further analysis.
The 10k pellet was enriched in markers for plasma mem-
branes and lysosomes, while the 150k pellet was enriched
in markers for ER and coated vesicles. HER14 cells were
either left unstimulated or stimulated for 10 min with 50
ng/ml EGF. The cells were subsequently fractionated, and
the different fractions were separated on SDS-PAGE. The
Western blots were probed with antibodies against Eps15,
a-adaptin, and the EGF receptor, and were analyzed by
densitometry, as described in Materials and Methods. As
expected, a-adaptin was mainly present in the 150k frac-
Figure 3. The active T963 EGF receptor mutant does not phos-
phorylate Eps15. Eps15 immunoprecipitates from HER14 cells and
NIH 3T3 cells stably transfected with a mutant EGF receptor
truncated at amino acid 963 (T963). Cells were either mock treated
or stimulated for 10 min with 50 ng/ml EGF. Immunoprecipitates
(A) and lysates (B) were separated on 10% SDS-PAGE, and the
Western blots were probed with an antiphosphotyrosine anti-
body.
Figure 4. Eps15 recruitment by the EGF receptor requires the
regulatory domain of the receptor. EGF receptor (EGF-R) im-
munoprecipitates from HER14 cells and NIH 3T3 cells stably
transfected with a mutant EGF receptor truncated at amino acid
963 (T963). Cells were either mock treated or stimulated for 10
min with 50 ng/ml EGF. Proteins were separated on 8% SDS-
PAGE, and the Western blot was probed with anti-Eps15 anti-
body (A), stripped, and subsequently probed with anti–EGF re-
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tion (Fig. 5 B), and a small amount was found in the 10k
fraction, probably associated to plasma membrane vesi-
cles, whereas the EGF receptor was detectable both in the 10k
and 150k fractions (Fig. 5 C). Both a-adaptin and the EGF
receptor were present in the total cell lysate, but the con-
centration of these proteins in this fraction was much
lower than in the enriched fractions. Eps15 was present in
all fractions (Fig. 5 A). Interestingly, EGF treatment re-
duced the amount of Eps15 in both the 10k and the 150k
fractions, while the amount of Eps15 in the total cell lysate
and the cytosol fraction remained constant. The drastic de-
crease in the amount of Eps15 in the 150k fraction after
EGF stimulation was z60%. Remarkably, the ratio be-
tween the 142- and 150-kD band of Eps15 was 1:1 in the
cytosol and 10k fraction, but 3:1 in the 150k fraction. In
conclusion, Eps15 is present in the cytosol, but also in the
fractions enriched in plasma membrane vesicles and clath-
rin-coated vesicles. Furthermore, EGF stimulation of cells
leads to the reduction in the amount of Eps15 present in
the fraction enriched in clathrin-coated vesicles.
Colocalization of Eps15 with a-Adaptin and Clathrin
Next, we analyzed the subcellular localization of Eps15,
a-adaptin, and clathrin LC using immunofluorescence mi-
croscopy. HER14 fibroblasts were fixed, permeabilized,
and stained with the relevant antibodies, and were subse-
quently analyzed in an immunofluorescence light micro-
scope. Staining the cells with anti-Eps15 antibodies obtains
a picture that reflects a clear punctate staining pattern
throughout the whole cell (Fig. 6, A and C). Staining of the
same cells with an anti–a-adaptin antibody revealed a sim-
ilar punctate staining pattern representing coated pits and
coated vesicles (Fig. 6 B; Guagliardi et al., 1990). Staining
with an anti–clathrin HC antibody led to a punctated pat-
tern throughout the cytoplasm representing endocytotic
vesicles, and to a perinuclear staining representing exocy-
totic vesicles from the TGN (Fig. 6 C). Comparison of
these images strongly suggests a colocalization of Eps15
with AP-2. The colocalization of Eps15 and clathrin HC is
only apparent in the endocytotic vesicles, but is absent in
the clathrin-coated vesicles in the perinuclear region (Fig.
6, A–D).
To verify these colocalization experiments, cells were ana-
lyzed using confocal scanning laser microscopy. HER14 cells
were labeled with anti-Eps15 antibody, which is seen as the
green stain (Fig. 7 A , column 1), and with anti–a-adaptin
antibody, which is seen as the red stain (Fig. 7 A, column
2). A clear colocalization between Eps15 and a-adaptin is
demonstrated by the yellow stain of the endocytic vesicles
(Fig. 7 A, columns 3 and 4). Labeling of cells with anti-
Eps15 (Fig. 7 B, column 1), together with anti–clathrin HC
(Fig. 7 A, column 2) revealed a punctate pattern for each
protein; however, only a partial colocalization was found,
visible as the yellow stain (Fig. 7 B, column 3 and 4). In
contrast to Eps15, clathrin showed additional staining sur-
rounding the nucleus. Both AP-2 and clathrin were
present in coated pits and coated vesicles, but not in early
endosomes. To determine whether Eps15 was located in
early endosomes, colocalization studies were performed
with the specific early endosome markers rab4 and rab5,
two members of the rab family of small ras-like, GTP-
binding proteins (Chavrier et al., 1990; van der Sluijs et al.,
1992). CHO cells stably transfected with cDNA of NH-
tagged rab4 and G-tagged rab5 (van der Sluijs, P., manu-
script submitted for publication) were stained with an
Eps15 antibody (Fig. 7, C and D, column 1), and with anti-
NH and anti-G antibodies (Fig. 7, C and D, column 2). Al-
though both stainings show a punctate labeling, no colo-
calization was found between Eps15 and rab4 or rab5, sug-
gesting that Eps15 is not present in early endosomes (Fig.
7, C and D, columns 3 and 4).
To rule out that the colocalization between Eps15 and
AP-2 or clathrin resulted from occasional overlap of ran-
domly distributed vesicles and to determine that the spatial
distribution of Eps15 and AP-2 or clathrin are positively
correlated, a cross-correlation function was calculated, as
developed by van Steensel and co-workers (1996). In a
graph showing the Dx over which the image has been
shifted on the x-axis and the Pearson’s correlation coeffi-
cient rP on the y-axis, a colocalization will show as a peak
with the maximum at Dx 5 0, exclusion will result in a dip
at Dx 5 0, while a random distribution will result in neither
a dip nor a peak. The rP is calculated as a measure of colo-
calization, and an rP of 1.0 indicates a 100% colocalization.
This cross-correlation analysis is depicted as a graph in
Fig. 6. This results for Eps15 and a-adaptin in a clear peak
at Dx 5 0 (red line) with a colocalization of z57%. For
Eps15 and clathrin, two different areas of the cell were an-
alyzed. Near the plasma membrane (blue line), a clear
colocalization of 55% was found, and the area around the
Golgi network (green line) showed a much lower colocal-
ization of 30% (the baseline of this graph starts at 0.2, and
therefore this value has to be deducted from the rP). In
contrast, the labeling of Eps15 together with either rab4 or
rab5 did not show any correlation (yellow and pink lines).
In conclusion, these colocalization experiments show
that Eps15 is present in clathrin-coated pits and vesicles
together with AP-2, whereas Eps15 is completely absent in
early endosomes.
Figure 5. Eps15 is present in the microsomal fraction after cell
fractionation. HER14 fibroblasts were used for cell fractionation
as described in Materials and Methods. Fractions were prepared
from cells that were either left unstimulated or stimulated with 50
ng/ml EGF for 10 min. The different fractions (25 mg per sample)
were separated by SDS-PAGE, and Western blots were probed
with an anti-Eps15 antibody (A), an anti–a-adaptin antibody (B),
and an anti–EGF receptor antibody (C).van Delft et al. Association and Colocalization of Eps15 with AP-2 and Clathrin 817
Eps15 Is Present in AP-2 and
Clathrin-stripped Membranes
The experiments described above demonstrate the associ-
ation of Eps15 with the EGF receptor, a-adaptin and
clathrin, which was confirmed by colocalization studies.
Furthermore, we have shown that Eps15 is located to
clathrin-coated pits and vesicles. It is not clear, however,
whether a-adaptin and clathrin are required for the local-
ization of Eps15 in coated vesicles. To investigate this,
HER14 cell membranes containing coated pits were iso-
lated according to the method of Chang et al. (1993a).
These membranes allow for the removal of clathrin from
coated pits by an incubation with a high pH buffer and the
AP-2 coat can be subsequently extracted by incubation of
the membranes with a 0.5-M Tris buffer (Unanue et al.,
1981). Under these conditions, the presence of Eps15 was
determined by immunolabeling. In untreated membranes,
labeling with anti-clathrin or anti–a-adaptin antibody
showed a clear punctate pattern similar to our previous re-
sults (Fig. 8, A and D). After treatment of the membranes
with a high pH buffer, clathrin HC labeling was absent
(Fig. 8 B), but AP-2 and Eps15 labeling was still present
(Fig. 8 E). Subsequent treatment with an 0.5 M Tris buffer
abolished AP-2 labeling (Fig. 8, C and F), which is in
agreement with previous results (Unanue et al., 1981; Chang
et al., 1993a). However, Eps15 staining of untreated mem-
brane fragments showed still a punctate pattern, similar to
the AP-2 and clathrin staining (Fig. 8 G). Interestingly, ex-
traction of both AP-2 and clathrin did not change this pat-
tern (Fig. 8, H and I). These data suggest that the presence
of Eps15 in coated pits is independent of a-adaptin or
clathrin.
Discussion
Eps15 is a substrate of the EGF receptor, and exhibits ho-
mology with the yeast protein End3, a protein involved in
the endocytosis of the a factor in S. cerevisiae (Fazioli et al.,
1993; Benedetti et al., 1994). Recently, Eps15 has been
shown to bind directly to the ear of a-adaptin, a compo-
nent of the AP-2 complex (Benmerah et al., 1995). In this
paper, we have investigated the possible role of Eps15 in
EGF receptor endocytosis. We have shown that Eps15
phosphorylation is mediated by the EGF receptor, and not
by PDGF or insulin receptors, which suggest a possible
function of Eps15 specifically in the endocytosis of EGF
receptors. Immunoprecipitation studies revealed that Eps15
can be co-immunoprecipitated with the EGF receptor.
Figure 6. Immunolocalization
of Eps15, a-adaptin, and clath-
rin  HC. HER14 cells were
grown in DME supple-
mented with 7.5% FCS, fixed
and permeabilized as de-
scribed in Materials and
Methods, and stained with
anti-Eps15 antibody (A and
C), anti–a-adaptin antibody
(B) or anti-clathrin HC anti-
body (D).The Journal of Cell Biology, Volume 136, 1997 818van Delft et al. Association and Colocalization of Eps15 with AP-2 and Clathrin 819
Moreover, the association of Eps15 with the EGF receptor
increased dramatically after activation of the receptor, while
the association of Eps15 with AP-2 or clathrin LC appeared
to occur independently of EGF. The association of Eps15
to the EGF receptor has not been reported before. In pre-
vious studies, Fazioli and co-workers did not detect Eps15
in EGF receptor immunoprecipitates. This difference is
probably caused by differences in receptor numbers of the
cell lines used.
A possible role for Eps15 in the endocytosis of EGF re-
ceptors was further investigated by subcellular localization
studies. Using a cell fractionation assay, we found that
Eps15 was present in the fractions enriched in plasma
membrane vesicles and in the fraction enriched in coated
vesicles. Furthermore, we have shown that the localization
of Eps15 resembled a staining pattern that is similar to
coated pits and coated vesicles. In localization experiments
using CLSM, it was shown that Eps15 colocalized with
AP-2, indicating that the association between Eps15 and
AP-2 is localized to coated pits and coated vesicles. A lo-
calization experiment with clathrin HC showed that Eps15
partially colocalized with this protein. Besides staining of
the endocytotic pits and vesicles, clathrin labeling showed
an additional staining in the perinuclear region, represent-
ing the exocytotic vesicles from the TGN (Robinson, 1987).
These data suggest an involvement of Eps15 in endocyto-
sis from the plasma membrane, but excludes an involve-
ment in exocytosis from the TGN. This is in agreement
with the fact that the function of Eps15 is EGF dependent.
Additional localization experiments showed no colocaliza-
tion between Eps15 and rab4 or rab5. Since both rab4 and
rab5 are specific early endosome markers, we conclude
that Eps15 is not present in early endosomes, but may
have a functional role in coated pits and coated vesicles.
Using light microscopy, we were not able to detect an ef-
fect of EGF on Eps15 distribution. Obviously, coated vesi-
cles do not redistribute dramatically upon growth factor
treatment. A drastic decrease upon EGF stimulation was
observed in the amount of Eps15 in the fraction enriched
in clathrin-coated vesicles. Interestingly, the ratio of the
140-kD and the modified form of Eps15 was reduced in
this fraction. This implies that clathrin-coated vesicles con-
tain more native Eps15 than the modified form of Eps15.
This can be explained in two ways. First, Eps15 modifica-
tion may reduce the binding of Eps15 to the clathrin coat,
and second, Eps15 modification may stimulate the uncoat-
ing of the coated vesicle. Further experiments are needed
to determine the role of Eps15 modification in EGF recep-
tor endocytosis.
An interesting question is where the binding site for
Eps15 is located on the EGF receptor. Alvarez and co-
workers (1995) have identified a domain of the EGF re-
ceptor that is essential for tyrosine phosphorylation of
Eps15. Possibly, this domain, encompassing residues 991–
1021 in the COOH-terminal part of the EGF receptor, is
not only required for Eps15 phosphorylation, but also for
Eps15 association to the EGF receptor. This result, how-
ever, was in contrast to the work of Fazioli and co-workers
(1993), who suggested that the juxtamembrane region is
required for Eps15 phosphorylation (Fazioli et al., 1993).
In this paper, we have shown that a mutant EGF receptor,
truncated at amino acid 963, can neither phosphorylate nor
bind Eps15, suggesting that the Eps15-bindings site is de-
leted or not functional in this mutant. All EGF receptor
mutants that have been described in this region (T973, T957,
and T963) have been shown to possess EGF-inducible ty-
rosine kinase activity, but they can no longer be internal-
ized (Chen et al., 1989). These data suggest that the regu-
latory domain in the COOH-terminal tail of the EGF
receptor is not only involved in endocytosis of the recep-
tor, but also in phosphorylation and binding of Eps15. In-
teresting in this respect is the difference between the EGF
receptor and the oncogenic family member ErbB2. Eps15
is a poor substrate for the ErbB2 receptor (Fazioli et al.,
1993), and the endocytosis of the ErbB2 receptor is im-
paired (Sorkin et al., 1993), supporting the suggestion of
Eps15 involvement in endocytosis of EGF receptors.
At the moment, it is also unclear which domain of Eps15
is involved in the association to the EGF receptor. Analy-
sis of Eps15-binding proteins by Far-Western blotting re-
vealed that protein association predominantly occurs with
the COOH-terminal part of the protein, domain I (Wong
et al., 1995). This domain contains three EH domains (Eps15
homology domain) that may be responsible for these in-
teractions (Wong et al., 1995). Domain II of Eps15 con-
tains an a-helical coiled-coil structure (Fazioli et al., 1993).
Coiled-coil structures have been shown to represent com-
mon protein-binding motifs, e.g., in subunits from inter-
mediate filaments. Domain III has been shown to bind
directly to the ear of a-adaptin and; furthermore, this do-
main contains a proline-rich motif that binds directly to
the oncogenic adaptor protein v-Crk (Benmerah et al.,
1995; Schumacher et al., 1995). v-Crk has been shown to
bind directly in vitro to the activated EGF receptor (Schu-
macher et al., 1995). At residue 992, the EGF receptor
contains a possible Crk-SH2 phosphotyrosine binding mo-
tif, YLIP (Songyang et al., 1993). It is tempting to specu-
late that the interaction between the EGF receptor and
Eps15 might be mediated by Crk. In this model, the SH2
domain of v-Crk may mediate the association to the ty-
rosine-phosphorylated EGF receptor, whereas the SH3 do-
main of v-Crk may be involved in the binding to the pro-
line-rich motif of Eps15 (Schumacher et al., 1995).
Although Crk binding to the EGF receptor has been de-
Figure 7. Colocalization studies of Eps15, a-adaptin and clathrin HC. HER14 cells were grown in DME supplemented with 7.5% FCS,
fixed and permeabilized as described in Materials and Methods, and stained with anti-Eps15 antibody (A and B, column 1) and anti–a-
adaptin antibody (A, column 2) or anti–clathrin HC antibody (B, column 2). Superimposed images of Eps15 and a-adaptin or Eps15 and
clathrin HC staining are shown in columns 3 and 4 (A and B). Likewise, CHO cells stably transfected with rab4 and rab5 cDNA were
stained with anti-Eps15 antibody (C and D, column 1) and anti-NH antibody (rab4; C, column 2) or anti-G antibody (rab5; D, column 2).
Superimposed images of Eps15 and rab4 or rab5 staining are shown in columns 3 and 4 (C and D). The graph represents the cross-corre-
lation function of the three-dimensional images indicated by the colored squares. For all cross-correlation functions, rP was determined
at Dx intervals of 0.4 mm.The Journal of Cell Biology, Volume 136, 1997 820
termined for v-Crk, it is possible that c-Crk will act in a sim-
ilar manner. Support for this hypothesis comes from the
T963 EGF receptor mutant, which lacks the putative Crk–
SH2 binding motif and neither binds nor phosphorylates
Eps15. Clearly, more research is required to determine the
domains of the EGF receptor and of Eps15, which are in-
volved in this interaction.
As shown in this study, Eps15 and a-adaptin are associ-
ated to each other in an EGF-independent manner. Both
proteins, however, bind the EGF receptor in an EGF-depen-
dent manner. This may suggest that either some receptors
will bind AP-2 and others will bind Eps15, or that the
binding of an Eps15–AP-2 complex to the EGF-receptor is
increased. Moreover, the clathrin triskelions might also be
components of the Eps15–AP-2 complex, since Eps15 is
present in a clathrin LC immunoprecipitate. However, the
clathrin LC could not be detected in an EGF receptor im-
munoprecipitate, which is in agreement with published
data (Boll et al., 1995; Sorkin and Carpenter, 1993). An
important question is whether AP-2 or clathrin are re-
Figure 8. Punctated Eps15 labeling on membranes after AP-2 and clathrin extraction. Membranes from HER14 cells were prepared by
rapid freeze-thaw rupturing of the cells. Membranes were left untreated (A, D, and G), treated with 20 mM TAPS buffer, pH 9.2 (B, E,
and H), or treated with 0.5 M Tris, pH 7.0 (C, F, and I). Subsequently, membranes were stained with anti–clathrin HC antibody (A–C),
anti–a-adaptin antibody (D–F) or anti-Eps15 antibody (G–I).van Delft et al. Association and Colocalization of Eps15 with AP-2 and Clathrin 821
quired for the presence of Eps15 in coated vesicles. To ad-
dress this question, we have demonstrated that in plasma
membranes stripped from AP-2 and clathrin, Eps15 was
still detectable in a staining pattern resembling that of AP-2
and clathrin. This observation suggests that neither AP-2 nor
clathrin are required for the presence of Eps15 in coated
vesicles.
In conclusion, our observations all point to the hypothe-
sis that Eps15 is involved in the internalization of EGF re-
ceptors via the coated vesicle pathway. Eps15 may medi-
ate the interaction between activated EGF receptors and
the coated pit. The increase of Eps15 binding to activated
EGF receptors suggests that Eps15 selectively recruits ac-
tivated EGF receptors to coated pits. The absence of Eps15
in the early endosome indicates that Eps15 functioning is
restricted to the early stages of EGF receptor internaliza-
tion.
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